Aprea Therapeutics, Inc. (APRE)
| Market Cap | 53.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.76M |
| Shares Out | 21.47M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313,436 |
| Open | 2.56 |
| Previous Close | 2.64 |
| Day's Range | 2.50 - 2.60 |
| 52-Week Range | 2.48 - 8.46 |
| Beta | -0.16 |
| Analysts | Hold |
| Price Target | 4.33 (+73.2%) |
| Earnings Date | Nov 4, 2021 |
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung ca...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for APRE stock is "Hold." The 12-month stock price forecast is 4.33, which is an increase of 73.20% from the latest price.
News
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst...
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Mai...
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant...
Got $5 to Spend on Penny Stocks? Check These 4 Out
Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malign...
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematolog...
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors. The trial is evaluating the safe...
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Cong...
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...
Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study
After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study. The trial is ...
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...
Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials
The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs. Approxi...
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...
Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Tr...
Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysp...
Implied Volatility Surging for Aprea (APRE) Stock Options
Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary effica...
STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2...
Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded
Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...
APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today
Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Sky...
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remis...
Why Aprea Therapeutics Shares Are Surging Today
Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met the ...